RESEARCHER PROFILE
Dr Erin Brazel
University of Adelaide
Filmed February 2024
Dr Erin Brazel has a background in molecular and translational microbiology, with a focus on developing new ways of preventing and treating bacterial diseases. Recently Dr Brazel has been awarded a Junior Fellowship by the Passe & Williams Memorial Foundation.
The fellowship enables outstanding individuals to obtain postdoctoral training under the supervision of an experienced clinical or scientific researcher, with the view to establishing a research career in Otolaryngology, Head and Neck Surgery in Australia and/or New Zealand.
The fellowship will support research on bacterial vaccines in a joint GPN Vaccines Ltd and the University of Adelaide project to explore combination vaccines for ear infections using Gamma-PN.
Bacterial ear infections are the most common bacterial disease affecting children. In Australia, episodes range from 1-2.4 million each year, affecting over 600,000 individuals, with 40% of these children experiencing six or more recurrences before the age of eight. Persistent cases can result in hearing loss and learning difficulties, leading to developmental delays and impacts on psychosocial health. Chronic ear infections have also been linked to increased rates of obesity during childhood and Later in life, which may be a result of prolonged antibiotic usage.
With antibiotic resistant superbugs projected to kill 10 million people each year by 2050, new ways of combatting disease are urgently required. A major focus of Dr Brazel’s research is the development of new vaccines to address emerging and existing pathogens that threaten global health and biosecurity. Vaccines are an important tool for reducing disease caused by antimicrobial resistant pathogens, the spread of resistant bacteria, and to reduce antimicrobial use in health and animal care.
Dr Brazel has contributed to the design and preclinical testing of many next generation vaccine candidates, including the current lead candidate (Gamma-PN3). This vaccine is currently being tested in a first-in-human Phase 1 clinical trial (commenced January 2023).
You Might also like
-
Vision impairment in children and the impact on children and their families
Dr Sue Silveira holds a conjoint academic position with Macquarie University and is the Course Director for their Master of Disability Studies, which is administered and delivered by NextSense Institute in affiliation with the University. She teaches in the areas of vision impairment and disability, and aims to share her knowledge while learning from others, especially people who are blind or have low vision and their families.
-
Genetic alterations in prostate cancer initiation and progression
Watch Dr Kelsie Raspin, a dedicated Postdoctoral Research Fellow specialising in Cancer Genetics at Menzies Institute for Medical Research, University of Tasmania, talk on bridging a critical knowledge gap in the understanding of genetic alterations implicated in prostate cancer initiation and its progression into metastatic forms.
-
Big data to improve the use of antidepressant medicines in aged care
Georgina Hughes is a pharmacist & PhD Candidate with the University of South Australia Clinical and Health Sciences and the Registry of Senior Australians (ROSA), undertaking research at South Australian Health and Medical Research Institute (SAHMRI).
Georgina’s PhD study and first published paper was on how to improve the safe and effective use of antidepressant medicines and optimise quality use of medicines in older people accessing residential aged care.